BOS161721

DRUG2 trials

Sponsors

Boston Pharmaceuticals

Conditions

Healthy ParticipantsSystemic Lupus Erythematosus

Phase 1

Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects

CompletedNCT03036865

Boston PharmaceuticalsHealthy Participants

Start: 2017-01-31End: 2018-04-27Updated: 2020-11-18

Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care

CompletedNCT03371251

Boston PharmaceuticalsSystemic Lupus Erythematosus

Start: 2018-01-10End: 2020-11-26Updated: 2022-03-14